Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 4/20 | 0.32 |
| ▸ | GRIN2D | O15399 | 3/20 | 0.32 |
| ▸ | GRIN3B | O60391 | 3/20 | 0.32 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.32 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.32 |
| ▸ | GRIN2A | Q12879 | 3/20 | 0.32 |
| ▸ | GRIN2C | Q14957 | 3/20 | 0.32 |
| ▸ | GRIN3A | Q8TCU5 | 3/20 | 0.32 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.32 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6135426 | 0.93 | GRIN2B (0.35) | GRIN2BGRIN2DGRIN3BADRA1AGRIN1 | |
| SCHEMBL3883554 | 0.85 | ALDH1A1 (0.33) | KDM4EMEN1MAPTKMT2A | |
| SCHEMBL28908500 | 0.68 | RARA (0.31) | — | |
| SCHEMBL31559989 | 0.65 | APP (0.34) | MEN1MAPTKMT2A | |
| SCHEMBL28768953 | 0.64 | RARA (0.33) | MAPT | |
| SCHEMBL4459328 | 0.64 | SRR (0.32) | — | |
| SCHEMBL27630130 | 0.64 | PTPN1 (0.33) | — | |
| SCHEMBL21043747 | 0.63 | PSEN1 (0.33) | — | |
| SCHEMBL28757628 | 0.63 | TSHR (0.41) | ADRA1AMEN1KMT2A | |
| SCHEMBL7327613 | 0.63 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1430025-B1 | METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING BACTERIAL INFECTION | ZHU DEXU (CN) | 2009-01-14 | — | — | EP | disclosed |
| US-6734212-B2 | ADMINISTERING AGENT THAT SELECTIVELY INHIBITS BACTERIAL DNA REPLICATION INITIATION; FOR DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH E. COLI OR H. PYLORI INFECTION | SHANGHAI EAST BEST BIOPHARMACEUTICAL (CN) | 2004-05-11 | — | — | US | disclosed |
| US-20030125384-A1 | Methods and compositions for treating or preventing bacterial infection | NANJING UNIVERSITY (CN) | 2003-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030125384-A1 | Methods and compositions for treating or preventing bacterial infection | MPO, TNF, APC | GRIN2B 4703/4885GRIN2D 4807/4885GRIN3B 4585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.